SCIENTIFIC RESULTS

PN6047 CONCISELY

Therapeutic focus » Scientific Results

Neuropathic pain therapy point by point

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

  • PN6047 is a novel fully patented molecule without any significant toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
  • PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes studied
  • PN6047 preferentially signals via Gi proteins compared with arrestin proteins
  • PN6047 has high potency and efficacy in reducing neuropathic pain in various animal models
  • PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
  • PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
  • PN6047 shows no histopathological  effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat neuropathic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

PN6047 versus conventional

The advantages of PN6047, versus current neuropathic pain medicines are potentially substantial.

vs Conventional Opioids:  
Better efficacy in sensory hypersensitivity disorders; no μ-opioids receptor side effects; no analgesic  tolerance; no abuse potential.

vs Gabapentin:
No dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
No cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more